---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-25-000109"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T20:53:56.967773+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MacroGenics Q3 net income $16.8M on $72.8M revenue; ends lorigerlimab prostate study; secures $75M partnership payments

## Summary
- Net income $16.8M ($0.27 diluted EPS) vs $56.3M ($0.90) in Q3 2024; revenue $72.8M down from $110.7M.
- Discontinued lorigerlimab in prostate cancer (LORIKEET) after interim data; continues LINNET ovarian study, update by mid-2026.
- Received $75M in new partnership payments: $50M from Sanofi (TZIELD milestones), $25M from Gilead (new preclinical program).
- Cash $146.4M at Sep 30, expected to add $75M in Q4; runway extended into late 2027.
- Three ADC programs advancing: MGC026 started Phase 1 expansion, MGC028 in Phase 1 dose escalation, MGC030 IND planned 2026.

## SEC filing metadata
- accession: 0001125345-25-000109
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534525000109/0001125345-25-000109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534525000109/mgnx-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-25-000109
- JSON: https://secwatch.observer/filing/0001125345-25-000109.json
- Plain text: https://secwatch.observer/filing/0001125345-25-000109.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.